GERMANTOWN, Md., July 18, 2019 /PRNewswire/ -- Neuralstem,
Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the
development of nervous system therapies based on its neural stem
cell and small molecule technologies, announced that Mary Ann Gray, Ph.D. has been appointed to the
Company's Board of Directors.
"We are pleased to welcome Mary
Ann to our board, her expertise and leadership
pharmaceutical and biotech industry will be a great asset to
Neuralstem," said Dr. Ken Carter,
Executive Chairman of the Board. "Both Dr. Gray's substantial
background in pharmacology and finance—as well as—her dedication to
developing new treatments, reflects our shared commitment here at
Neuralstem to improve patient outcomes. We welcome her insight as
we continue to grow and develop innovative therapies."
"I am thrilled to join the Neuralstem team and I look forward to
working with a company dedicated to expanding the industry with
novel therapies for patients and to provide our shareholders with a
sound investment," said Dr. Mary Ann
Gray.
Dr. Gray has a distinguished scientific background, completing
pharmacology research in tumor biology, including the impact of
therapeutics on cardiac membranes. With an early career as a
scientist focused on new drug development, she subsequently worked
in equities research before becoming a senior analyst and portfolio
manager. The combination of scientific and financial expertise
provides unique insights for board leadership. She most recently
served on the boards of Senomyx, and Juniper Pharmaceuticals, both
companies were recently acquired. Dr. Gray has served on several
public-company boards over the last 15 years including, TetraLogic,
a publicly-held clinical-stage biopharmaceutical company focused on
oncology and infectious diseases, Dyax Corp., a rare disease
company acquired by Shire in 2016; and ACADIA Pharmaceuticals,
focused on commercialization of CNS therapies. She currently sits
on the board of Sarepta, a precision medicine company with assets
in rare neuromuscular diseases, including gene therapy for DMD. She
is President of Gray Strategic Advisors, LLC, a biotechnology
strategic planning and advisory firm.
Dr. Gray holds a Bachelor of Science degree from University of South Carolina, a Ph.D. in
pharmacology from the University of
Vermont, and completed her post-doctoral work at
Northwestern University Medical School
and at the Yale University School of
Medicine.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company
developing novel treatments for nervous system diseases of high
unmet medical need. Neuralstem's diversified portfolio of product
candidates includes its proprietary neural stem cell
technology.
The Company has two lead development candidates:
NSI-566 is a neural stem cell therapy in clinical development
for treatment of paralysis in stroke, for Amyotrophic Lateral
Sclerosis (ALS) and for chronic spinal cord injury (cSCI).
NSI-189 is a small molecule in clinical development for major
depressive disorder (MDD) and in preclinical development for
Angelman syndrome, irradiation-induced cognitive impairment, Type 1
and Type 2 diabetes, and stroke.
Cautionary Statement Regarding Forward Looking Information
This news release contains "forward-looking statements" made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
relate to future, not past, events and may often be identified by
words such as "expect," "anticipate," "intend," "plan," "believe,"
"seek" or "will." Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Specific
risks and uncertainties that could cause our actual results to
differ materially from those expressed in our forward-looking
statements include risks inherent in the development and
commercialization of potential products, uncertainty of clinical
trial results or regulatory approvals or clearances, need for
future capital, dependence upon collaborators and maintenance of
our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Neuralstem's periodic reports, including its
Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and
Exchange Commission (SEC), and in other reports filed with the SEC.
We do not assume any obligation to update any forward-looking
statements.
Investor Contact:
Hibiscus Bioventures
josh@hibiscusbio.com
View original
content:http://www.prnewswire.com/news-releases/neuralstem-appoints-mary-ann-gray-phd-to-board-of-directors-300885589.html
SOURCE Neuralstem, Inc.